Mineralys Therapeutics (MLYS)
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is...
- Open
- 24.010
- High
- 24.340
- Low
- 23.550
- Prev. Close
- 23.720
- Volume
- 928.30K
- Turnover
- 22.06M
- Avg Price
- 23.761
- Bid/Ask Ratio
- --
- Amplitude
- 3.33%
- 52wk High
- 47.650
- Volume Ratio
- 1.41
- Turnover Ratio
- 1.40%
- 52wk Low
- 22.300
- Float Mkt Cap
- 1.57B
- Market CapUSD
- 2.09B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -3.95
- EPSDynamic
- -6.34
- EPSStatic
- --
- BVPS
- 6.23
- P/B
- 3.79
- Circulating Supply
- 66.52M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 88.41M
- Min lot size
- 1
- Currency
- USD
Mineralys Therapeutics Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$48.50105.25%
Forecast & RatingStrong buy
10analysts
- Strong buy90.00%
- Buy0.00%
- Hold10.00%
- Sell0.00%
- Strong sell0.00%
News
- Simplywall · 14 hours ago
Will AHA Trial Data Change Mineralys Therapeutics (MLYS) Narrative
- PUBT · 1 day ago, 09:54 PM
Mineralys Therapeutics CEO Jon Congleton disposes of $1,909,665 common shares
- StockTitan · 2 days ago, 12:30 PM
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 | MLYS Stock News
- Unusual Whales · Oct 1 at 08:07 PM
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
- PUBT · Oct 1 at 08:06 PM
Mineralys to present lorundrostat Explore-OSA hypertension trial data at AHA Hypertension Scientific Sessions 2026
- Market Beat · Oct 1 at 07:22 PM
Mineralys Therapeutics (NASDAQ:MLYS) Stock Falls 6.1% - What's Next?
